Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 4, 2015, Pages 1003-1018

  Gharagozloo, Marjan ^a   Majewski, Slawomir ^b   Foldvari, Marianna ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Autoimmune diseases; Drug delivery; Immunosuppression; Nanomedicine; Tolerance

Indexed keywords

CONTROLLED DRUG DELIVERY; DERMATOLOGY; DISEASE CONTROL; DRUG DELIVERY; FITS AND TOLERANCES; MEDICAL NANOTECHNOLOGY; PATHOLOGY; TARGETED DRUG DELIVERY;

AUTOIMMUNE DISEASE; BIOLOGICAL THERAPIES; FUNCTIONAL DISABILITIES; IMMUNOMODULATORY AGENTS; IMMUNOSUPPRESSION; MULTIPLE ORGAN FAILURE; THERAPEUTIC APPLICATION; TOLERANCE INDUCTIONS;

DISEASES;

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; OFATUMUMAB; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SMALL INTERFERING RNA; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CROHN DISEASE; DENDRITIC CELL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; EXOME; GENE THERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PEMPHIGUS VULGARIS; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VITILIGO; ANIMAL; AUTOIMMUNE DISEASES; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; NANOMEDICINE;

EID: 84929316338     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.12.003     Document Type: Review

References (101)

1. Zen M., Gatto M., Domeneghetti M., Palma L., Borella E., Iaccarino L., et al. Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review. Clin Rev Allergy Immunol 2013, 45(2):227-235.
2. Paul W.E. Fundamental Immunology 2008, Wolters Kluwer/Lippincott Williams & Wilkins.
3. Murphy K.P., Travers P., Walport M., Janeway C. Janeway's immunobiology: Garland Science 2012.
4. Male D.K., Brostoff J., Roth D., Roitt I. Immunology 2012, Elsevier/Saunders.
5. Ruocco E., Wolf R., Ruocco V., Brunetti G., Romano F., Lo Schiavo A. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol 2013, 31(4):382-390.
6. Kovarik J.M., Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs 2003, 8(1):47-62.
7. Rosman Z., Shoenfeld Y., Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013, 11:88.
8. Dinarello C.A. Anti-inflammatory Agents: Present and Future. Cell 2010, 140(6):935-950.
9. Abolmaali S.S., Tamaddon A.M., Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol 2013, 71(5):1115-1130.
10. Burli R.W., Haughan A.F., Hodges A.J. Development of small-molecule therapies for autoimmune diseases. Autoimmunity 2010, 43(7):526-538.
11. Tarner I.H., Muller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 2008, 5(9):1027-1037.
12. van den Hoven J.M., Van Tomme S.R., Metselaar J.M., Nuijen B., Beijnen J.H., Storm G. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm 2011, 8(4):1002-1015.
13. Jain K.K. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine 2012, 7(8):1225-1233.
14. Schneider M., Stracke F., Hansen S., Schaefer U.F. Nanoparticles and their interactions with the dermal barrier. Dermatol Endocrinol 2009, 1(4):197-206.
15. Clemente-Casares X., Santamaria P. Nanomedicine in autoimmunity. Immunol Lett 2014, 158(1-2):167-174.
16. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65(1):36-48.
17. Komano Y., Yagi N., Onoue I., Kaneko K., Miyasaka N., Nanki T. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis. J Pharmacol Exp Ther 2012, 340(1):109-113.
18. Badea I., Virtanen C., Verrall R.E., Rosenberg A., Foldvari M. Effect of topical interferon-gamma gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/+ mice. Gene Ther 2012, 19(10):978-987.
19. Banerjee A., Onyuksel H. Peptide delivery using phospholipid micelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4(5):562-574.
20. Metselaar J.M., Wauben M.H., Wagenaar-Hilbers J., Boerman O.C., Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003, 48(7):2059-2066.
21. Rao V., Bowman S. Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis 2013, 5(4):234-249.
22. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.
23. Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin Exp Immunol 2003, 132(2):185-192.
24. Kopf M., Bachmann M.F., Marsland B.J. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 2010, 9(9):703-718.
25. Mullen L., Adams G., Layward L., Vessillier S., Annenkov A., Mittal G., et al. Latent cytokines for targeted therapy of inflammatory disorders. Expert Opin Drug Deliv 2014, 11(1):101-110.
26. Madry H., Orth P., Cucchiarini M. Gene therapy for cartilage repair. Cartilage 2011, 2(3):201-225.
27. Lee J.-M., Yoon T.-J., Cho Y.-S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed Res Int 2013, 2013:782041.
28. Kapoor B., Singh S.K., Gulati M., Gupta R., Vaidya Y. Application of liposomes in treatment of rheumatoid arthritis: Quo vadis. Scientific World Journal 2014, [Article ID 978351, 17 pages].
29. Khoury M., Louis-Plence P., Escriou V., Noel D., Largeau C., Cantos C., et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 2006, 54(6):1867-1877.
30. Prabhu P., Shetty R., Koland M., Vijayanarayana K., Vijayalakshmi K.K., Nairy M.H., et al. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomedicine 2012, 7:177-186.
31. Khoury M., Escriou V., Courties G., Galy A., Yao R., Largeau C., et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 2008, 58(8):2356-2367.
32. Boissier M.C. Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine 2011, 78(3):230-234.
33. Che L., Zhou J., Li S., He H., Zhu Y., Zhou X., et al. Assembled nanomedicines as efficient and safe therapeutics for articular inflammation. Int J Pharm 2012, 439(1-2):307-316.
34. Howard K.A., Paludan S.R., Behlke M.A., Besenbacher F., Deleuran B., Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009, 17(1):162-168.
35. te Boekhorst B.C., Jensen L.B., Colombo S., Varkouhi A.K., Schiffelers R.M., Lammers T., et al. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. J Control Release 2012, 161(3):772-780.
36. Desai P.R., Marepally S., Patel A.R., Voshavar C., Chaudhuri A., Singh M. Topical delivery of anti-TNFalpha siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release 2013, 170(1):51-63.
37. Evans C.H., Ghivizzani S.C., Robbins P.D. Arthritis gene therapy and its tortuous path into the clinic. Transl Res 2013, 161(4):205-216.
38. Seroogy C., Fathman C. The application of gene therapy in autoimmune diseases. Gene Ther 2000, 7(1):9-13.
39. Moon J.J., Huang B., Irvine D.J. Engineering nano- and microparticles to tune immunity. Adv Mater 2012, 24(28):3724-3746.
40. Basarkar A., Singh J. Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm Res 2009, 26(1):72-81.
41. Wettig S.D., Verrall R.E., Foldvari M. Gemini surfactants: a new family of building blocks for non-viral gene delivery systems. Curr Gene Ther 2008, 8(1):9-23.
42. Badea I., Verrall R., Baca-Estrada M., Tikoo S., Rosenberg A., Kumar P., et al. In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes. J Gene Med 2005, 7(9):1200-1214.
43. Badea I., Wettig S., Verrall R., Foldvari M. Topical non-invasive gene delivery using gemini nanoparticles in interferon-γ-deficient mice. Eur J Pharm Biopharm 2007, 65(3):414-422.
44. Evans C. Arthritis gene therapy trials reach phase II. J Rheumatol 2010, 37(4):683-685.
45. Eulberg D., Klussmann S. Spiegelmers: biostable aptamers. Chembiochem 2003, 4(10):979-983.
46. Sundaram P., Kurniawan H., Byrne M.E., Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 2013, 48(1-2):259-271.
47. Purschke W.G., Hoehlig K., Buchner K., Zboralski D., Schwoebel F., Vater A., et al. Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes Sphingosine-1-Phosphate, a central mediator of angiogenesis. Biochem J 2014, 462(1):153-162.
48. Battaglia M., Stabilini A., Tresoldi E. Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol 2012, 821:279-293.
49. Tresoldi E., Dell'Albani I., Stabilini A., Jofra T., Valle A., Gagliani N., et al. Stability of human rapamycin-expanded CD4+ CD25+ T regulatory cells. Haematologica 2011, 96(9):1357-1365.
50. Zeng H., Chi H. mTOR signaling and transcriptional regulation in T lymphocytes. Transcription 2014, 5.
51. Cobbold S.P., Waldmann H. Regulatory Cells and Transplantation Tolerance. Cold Spring Harb Perspect Med 2013, 3(6):a015545.
52. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8(6):2101-2141.
53. Shen L.-J., Wu F.-L.L. Nanomedicines in renal transplant rejection-focus on sirolimus. Int J Nanomedicine 2007, 2(1):25.
54. Junghanns J.-U.A., Müller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008, 3(3):295.
55. Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics 2013, 7:131-138.
56. Calabresi P.A., Kieseier B.C., Arnold D.L., Balcer L.J., Boyko A., Pelletier J., et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014, 13(7):657-665.
57. Markatseli T., Papagoras C., Nikoli A., Voulgari P., Drosos A. Certolizumab for rheumatoid arthritis. Clin Exp Rheumatol 2014, 32(3):415-423.
58. Deeks E.D. Certolizumab Pegol. Drugs 2013, 73(1):75-97.
59. Dinesen L., Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007, 2(1):39.
60. Shah M., Edman M.C., Janga S.R., Shi P., Dhandhukia J., Liu S., et al. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. J Control Release 2013, 171(3):269-279.
61. Belogurov A.A., Stepanov A.V., Smirnov I.V., Melamed D., Bacon A., Mamedov A.E., et al. Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J 2013, 27(1):222-231.
62. Jain A., Jain A., Gulbake A., Shilpi S., Hurkat P., Jain S.K. Peptide and protein delivery using new drug delivery systems. Crit Rev Ther Drug Carrier Syst 2013, 30(4).
63. Buyuktimkin B., Wang Q., Kiptoo P., Stewart J.M., Berkland C., Siahaan T.J. Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Mol Pharm 2012, 9(4):979-985.
64. Zhao H., Kiptoo P., Williams T.D., Siahaan T.J., Topp E.M. Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model. J Control Release 2010, 141(2):145-152.
65. Delgado M., Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids 2013, 45(1):25-39.
66. Koo O.M.Y., Rubinstein I., Önyüksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res 2011, 28(4):776-787.
67. Sethi V., Rubinstein I., Kuzmis A., Kastrissios H., Artwohl J., Onyuksel H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol Pharm 2013, 10(2):728-738.
68. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24(10):1211-1217.
69. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013, 12(5):543-553.
70. Mahurkar S., Suppiah V., O'Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev 2014, 13(2):178-186.
71. Kooijmans K.S.A., Vader P., van Dommelen S.M., van Solinge W.W., Schiffelers R.M. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine 2012, 7:1525-1541.
72. Yang C., Robbins P.D. Immunosuppressive exosomes: a new approach for treating arthritis. Int J Rheum 2012, 2012:573528.
73. Yin W., Ouyang S., Li Y., Xiao B., Yang H. Immature dendritic cell-derived exosomes: A promise subcellular vaccine for autoimmunity. Inflammation 2013, 36(1):232-240.
74. Kannan K., Ortmann R.A., Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005, 12(3):167-181.
75. Kim S.H., Bianco N.R., Shufesky W.J., Morelli A.E., Robbins P.D. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol 2007, 179(4):2242-2249.
76. Cai Z., Zhang W., Yang F., Yu L., Yu Z., Pan J., et al. Immunosuppressive exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res 2011, 22(3):607-610.
77. Faria A., Weiner H.L. Oral tolerance. Immunol Rev 2005, 206(1):232-259.
78. Kaur A., Harikumar S. Controlled Drug Delivery Approaches for Rheumatoid Arthritis. J Appl Pharm Sci 2012, 2(08):21-32.
79. Türker S., Erdogan S., Özer Y.A., Bilgili H., Deveci S. Enhanced efficacy of diclofenac sodium-loaded lipogelosome formulation in intra-articular treatment of rheumatoid arthritis. J Drug Target 2008, 16(1):51-57.
80. Bader R.A. The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment. Rheumatoid Arthritis Treatment 2012, [ISBN: 978-953-307-850-2, InTech]. A. Lemmey (Ed.).
81. Kim W.U., Lee W.K., Ryoo J.W., Kim S.H., Kim J., Youn J., et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 2002, 46(4):1109-1120.
82. Goldenberg M.M. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999, 21(9):1497-1513.
83. Klippstein R., Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 2010, 6(4):523-529.
84. Lutterotti A., Yousef S., Sputtek A., Sturner K.H., Stellmann J.P., Breiden P., et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013, 5(188):188ra75.
85. Tse M.T. Immunomodulators: particulate promotion of tolerance. Nat Rev Drug Discov 2013, 12(1):22-23.
86. Getts D.R., Martin A.J., McCarthy D.P., Terry R.L., Hunter Z.N., Yap W.T., et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012, 30(12):1217-1224.
87. Hunter Z., McCarthy D.P., Yap W.T., Harp C.T., Getts D.R., Shea L.D., et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 2014, 8(3):2148-2160.
88. Prasad S., Xu D., Miller S.D. Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes. Rev Diabet Stud 2012, 9(4):319-327.
89. Clemente-Casares X., Tsai S., Huang C., Santamaria P. Antigen-specific therapeutic approaches in Type 1 diabetes. Cold Spring Harb Perspect Med 2012, 2(2):a007773.
90. Tsai S., Shameli A., Yamanouchi J., Clemente-Casares X., Wang J., Serra P., et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010, 32(4):568-580.
91. Feldmann M., Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005, 435(7042):612-619.
92. Yuan B., Zhao L., Fu F., Liu Y., Lin C., Wu X., et al. A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis. Mol Immunol 2014, 57(2):93-99.
93. Quintana F.J. Nanoparticles for the induction of antigen-specific Tregs. Immunotherapy 2013, 5(5):437-440.
94. Gandhi R., Kumar D., Burns E.J., Nadeau M., Dake B., Laroni A., et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010, 11(9):846-853.
95. Yeste A., Nadeau M., Burns E.J., Weiner H.L., Quintana F.J. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2012, 109(28):11270-11275.
96. Look M., Stern E., Wang Q.A., DiPlacido L.D., Kashgarian M., Craft J., et al. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest 2013, 123(4):1741.
97. Look M., Saltzman W.M., Craft J., Fahmy T.M. The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials 2014, 35(3):1089-1095.
98. Ishiguro A., Akiyama T., Adachi H., Inoue J., Nakamura Y. Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum 2011, 63(2):455-466.
99. Yuan B., Zhao L., Fu F., Liu Y., Lin C., Wu X., et al. A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis. Mol Immunol 2013, 57(2):93-99.
100. Kotsovilis S., Andreakos E. Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol 2014, 1060:37-59.
101. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61(9):2340-2348.